modified Shenling Baizhu San
Phase 2Small molecule
modified Shenling Baizhu San is one of 66 small molecule programs targeting Insomnia. It is currently in Phase 2.
3
Indications
6
Total Trials
2
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Rezzayo
RochePhase 3
Daliresp
AstraZenecaPhase 3
Skyrizi
AbbViePhase 3
Cytosar
TevaPhase 3
Fludara
SanofiPhase 3
Celestone
SSchering-Plough
Phase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
EBGLYSS
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis2 trials
Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children
Unknown status·—·Phase 2/3·NCT04419584·64 enrolled
Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children
Unknown status·—·Phase 1/2·NCT05613062·20 enrolled
Menopausal Syndrome1 trial
RCT on the Treatment of Menopausal Syndrome With Chinese Medicine
Unknown status·—·Phase 2·NCT06074809·78 enrolled
Insomnia1 trial
Chinese Medicine in Treating Insomnia
Not yet recruiting·—·Phase 2·NCT06511011·76 enrolled
Pneumoconiosis1 trial
Evaluating the Efficacy and Safety of Modified Qing-Zao-Jiu-Fei Decoction on Pneumoconiosis Patients
Not yet recruiting·—·Phase 2·NCT07178184·80 enrolled
Macular Edema1 trial
An Innovative Chinese Herbal Formula for Macular Edema
Unknown status·—·Phase 2·NCT05122702·70 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CChinese University of Hong Kong